Compare · CLOV vs NTRA
CLOV vs NTRA
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $29.60B, about 20.8x CLOV ($1.42B).
- Over the past year, CLOV is down 18.7% and NTRA is up 32.2% - NTRA leads by 51.0 points.
- NTRA has been more active in the news (24 items in the past 4 weeks vs 15 for CLOV).
- NTRA has more recent analyst coverage (25 ratings vs 12 for CLOV).
- Company
- Clover Health Investments Corp.
- Natera Inc.
- Price
- $2.71-1.45%
- $207.29+0.42%
- Market cap
- $1.42B
- $29.60B
- 1M return
- +58.48%
- +1.98%
- 1Y return
- -18.74%
- +32.25%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 15
- 24
- Recent ratings
- 12
- 25
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CLOV
- SEC Form DEFA14A filed by Clover Health Investments Corp.
- SEC Form DEF 14A filed by Clover Health Investments Corp.
- SEC Form 4 filed by Priest Brady Patrick
- SEC Form 4 filed by Priest Brady Patrick
- SEC Form 4 filed by Soares Karen
- SEC Form 4 filed by Toy Andrew
- SEC Form 4 filed by Thornton Joseph Clay
- SEC Form 4 filed by Reynoso Jamie L.
- SEC Form 4 filed by Wai Conrad
- SEC Form 3 filed by new insider Oldakowski Joseph Frank
Latest NTRA
- Natera to Report its First Quarter Results on May 7, 2026
- CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $1,001,645 worth of shares (5,063 units at $197.84) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 58,291 units (SEC Form 4) (withholding obligation)
- CEO AND PRESIDENT Chapman Steven Leonard sold $1,191,775 worth of shares (5,838 units at $204.14) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 150,769 units (SEC Form 4) to satisfy tax liability
- CO-FOUNDER Sheena Jonathan sold $699,693 worth of shares (3,544 units at $197.43) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 255,711 units (SEC Form 4) (withholding obligation)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $379,811 worth of shares (1,861 units at $204.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.83% to 223,024 units (SEC Form 4) (tax liability)
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $344,517 worth of shares (1,688 units at $204.10) as part of a pre-agreed trading plan, decreasing direct ownership by 0.89% to 187,511 units (SEC Form 4) to cover taxes
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $445,341 worth of shares (2,182 units at $204.10) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 145,700 units (SEC Form 4) (withholding tax)
- Director Marcus Gail Boxer was granted 330 shares, increasing direct ownership by 6% to 6,183 units (SEC Form 4)
- Director Baynes Roy D. was granted 83 shares, increasing direct ownership by 0.45% to 18,512 units (SEC Form 4)
- Director Bertagnolli Monica was granted 83 shares, increasing direct ownership by 2% to 5,374 units (SEC Form 4)